A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (NCT06500702)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Biopsy report indicative of primary FSGS or MCD, with supportive clinical presentation per Investigator's judgement.
2. UPCR ≥3 g/g at screening, or ≥ 1.5 g/g in those with eGFR ≥ 60 mL/min/1.73 m2.
3. eGFR ≥45 mL/min/1.73 m\^2 at screening.
4. Documented history of UPCR or UACR (or 24-hour urine protein or 24-hour urine albumin) reduction by \>40% in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥3.5 g/g or equivalent for UACR (or pre-treatment 24-hr urine protein was ≥3.5 g/day if 24-hour urine protein is used or equivalent for 24-hr urine albumin if 24-hour urine albumin is used).
5. ≤10 mg/day prednisone or equivalent and stable starting at least 1 week prior to randomization.
6. For those on a RAAS inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting RAAS inhibitors or changing the dose will not be allowed during the double-blind or OLE treatment period.
7. For those on an SGLT2 inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting SGLT2 inhibitor treatment or changing the dose will not be allowed during the double-blind or OLE treatment periods.
8. Body weight within 45 to 120 kg (inclusive) at screening.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (71 Sites)

• Investigational Site Number : 8400007 — Birmingham, Alabama
• Investigational Site Number : 8400015 — Orange, California
• Investigational Site Number : 8400012 — San Francisco, California
• Investigational Site Number : 8400025 — Tampa, Florida
• Emory Children's Center- Site Number : 8400020 — Atlanta, Georgia
• Investigational Site Number : 8400014 — Chicago, Illinois
• Investigational Site Number : 8400017 — Hinsdale, Illinois
• Investigational Site Number : 8400010 — Ann Arbor, Michigan
• Investigational Site Number : 8400019 — Edina, Minnesota
• Investigational Site Number : 8400018 — Las Vegas, Nevada
• Investigational Site Number: 8400028 — Albuquerque, New Mexico
• Investigational Site Number : 8400001 — New York, New York
• Investigational Site Number : 8400021 — Chapel Hill, North Carolina
• Investigational Site Number : 8400024 — Dallas, Texas
• Investigational Site Number : 8400005 — El Paso, Texas
• Investigational Site Number: 8400016 — Houston, Texas
• Investigational Site Number : 0320001 — Buenos Aires,
• Investigational Site Number : 0320002 — Córdoba,
• Investigational Site Number : 0360003 — Garran, Australian Capital Territory
• Investigational Site Number : 0360001 — Parkville, Victoria
• Investigational Site Number: 0760004 — Botucatu, São Paulo
• Synvia Clinical- Site Number : 0760005 — São Paulo, São Paulo
• Investigational Site Number : 0760002 — São Paulo,
• Investigational Site Number : 0760001 — São Paulo,
• Investigational Site Number : 1240002 — London, Ontario

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.